Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2015 Oct 27

PMID 26502061

Citations 31

Authors

Mario Fiore

Stefano Forli

Fabrizio Manetti

Affiliations

Soon will be listed here.

Abstract

The p38/MAPK-activated kinase 2 (MK2) pathway is involved in a series of pathological conditions (inflammation diseases and metastasis) and in the resistance mechanism to antitumor agents. None of the p38 inhibitors entered advanced clinical trials because of their unwanted systemic side effects. For this reason, MK2 was identified as an alternative target to block the pathway but avoiding the side effects of p38 inhibition. However, ATP-competitive MK2 inhibitors suffered from low solubility, poor cell permeability, and scarce kinase selectivity. Fortunately, non-ATP-competitive inhibitors of MK2 have been already discovered that allowed circumventing the selectivity issue. These compounds showed the additional advantage to be effective at lower concentrations in comparison to the ATP-competitive inhibitors. Therefore, although the significant difficulties encountered during the development of these inhibitors, MK2 is still considered as an attractive target to treat inflammation and related diseases to prevent tumor metastasis and to increase tumor sensitivity to chemotherapeutics.

Citing Articles

Remodeling tumor-associated macrophage for anti-cancer effects by rational design of irreversible inhibition of mitogen-activated protein kinase-activated protein kinase 2.

Wang D, Sun D, Wang X, Peng X, Ji Y, Tang L MedComm (2020). 2024; 5(7):e634.

PMID: 38988492 PMC: 11233931. DOI: 10.1002/mco2.634.

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab.

Wojcik M, Plata-Babula A, Glowaczewska A, Sirek T, Orczyk A, Malecka M Cell Cycle. 2024; 23(4):385-404.

PMID: 38557266 PMC: 11174132. DOI: 10.1080/15384101.2024.2335051.

Recent Advancements in the Treatment of Alzheimer's Disease: A Multitarget-directed Ligand Approach.

Kumar S, Mahajan A, Ambatwar R, Khatik G Curr Med Chem. 2023; 31(37):6032-6062.

PMID: 37861025 DOI: 10.2174/0109298673264076230921065945.

Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i).

Ganguly P, Macleod T, Wong C, Harland M, McGonagle D Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765094 PMC: 10537904. DOI: 10.3390/ph16091286.

Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment.

Alimbetov D, Umbayev B, Tsoy A, Begimbetova D, Davis T, Kipling D BMC Cancer. 2023; 23(1):895.

PMID: 37740222 PMC: 10517462. DOI: 10.1186/s12885-023-11319-x.

References

Kosugi T, Mitchell D, Fujino A, Imai M, Kambe M, Kobayashi S . Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach. J Med Chem. 2012; 55(15):6700-15. DOI: 10.1021/jm300411k. View

White A, Pargellis C, Studts J, Werneburg B, Farmer 2nd B . Molecular basis of MAPK-activated protein kinase 2:p38 assembly. Proc Natl Acad Sci U S A. 2007; 104(15):6353-8. PMC: 1851067. DOI: 10.1073/pnas.0701679104. View

Liu C, Lin J, Hynes J, Wu H, Wrobleski S, Lin S . Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor. J Med Chem. 2015; 58(19):7775-84. DOI: 10.1021/acs.jmedchem.5b00839. View

Hao M, Ren H, Luo F, Zhang S, Qiu J, Ji M . A computational study on thiourea analogs as potent MK-2 inhibitors. Int J Mol Sci. 2012; 13(6):7057-7079. PMC: 3397511. DOI: 10.3390/ijms13067057. View

Huang X, Zhu X, Chen X, Zhou W, Xiao D, Degrado S . A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett. 2011; 22(1):65-70. DOI: 10.1016/j.bmcl.2011.11.074. View

Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, LUTSCH G, Ducasse C . Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem. 1999; 274(27):18947-56. DOI: 10.1074/jbc.274.27.18947. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Trempolec N, Dave-Coll N, Nebreda A . SnapShot: p38 MAPK substrates. Cell. 2013; 152(4):924-924.e1. DOI: 10.1016/j.cell.2013.01.047. View

Lovering F, Kirincich S, Wang W, Combs K, Resnick L, Sabalski J . Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009; 17(9):3342-51. DOI: 10.1016/j.bmc.2009.03.041. View

10.

Velcicky J, Feifel R, Hawtin S, Heng R, Huppertz C, Koch G . Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. Bioorg Med Chem Lett. 2010; 20(3):1293-7. DOI: 10.1016/j.bmcl.2009.10.138. View

11.

Anderson D, Hegde S, Reinhard E, Gomez L, Vernier W, Lee L . Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett. 2005; 15(6):1587-90. DOI: 10.1016/j.bmcl.2005.01.067. View

12.

Ge X, Lyu P, Gu Y, Li L, Li J, Wang Y . Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation. Biochem Biophys Res Commun. 2015; 464(3):862-8. DOI: 10.1016/j.bbrc.2015.07.052. View

13.

Gurgis F, Ziaziaris W, Munoz L . Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Mol Pharmacol. 2013; 85(2):345-56. DOI: 10.1124/mol.113.090365. View

14.

Brugnano J, Chan B, Seal B, Panitch A . Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. J Control Release. 2011; 155(2):128-33. DOI: 10.1016/j.jconrel.2011.05.007. View

15.

Norman P . Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015; 24(3):383-92. DOI: 10.1517/13543784.2015.1006358. View

16.

Argiriadi M, Ericsson A, Harris C, Banach D, Borhani D, Calderwood D . 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Bioorg Med Chem Lett. 2009; 20(1):330-3. DOI: 10.1016/j.bmcl.2009.10.102. View

17.

Manetti F . LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev. 2012; 32(5):968-98. DOI: 10.1002/med.20230. View

18.

Huang X, Shipps Jr G, Cheng C, Spacciapoli P, Zhang X, McCoy M . Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors. ACS Med Chem Lett. 2014; 2(8):632-7. PMC: 4017987. DOI: 10.1021/ml200113y. View

19.

Xiao D, Palani A, Huang X, Sofolarides M, Zhou W, Chen X . Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorg Med Chem Lett. 2013; 23(11):3262-6. DOI: 10.1016/j.bmcl.2013.03.109. View

20.

Davis T, Bagley M, Dix M, Murziani P, Rokicki M, Widdowson C . Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007; 17(24):6832-5. DOI: 10.1016/j.bmcl.2007.10.036. View